Nelson Dusetti shared on X:
“Grateful to Institut National Du Cancer for funding through the PRT-K 2024 program!
This support helps us study treatment resistance in pancreatic cancer, strengthening the collaboration between CRCM – Cancer Research Centre of Marseille and Paoli-Calmettes Institute.”
Additional information.
Source: Nelson Dusetti/X
Nelson Dusetii is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
